NEUP
NASDAQ · Biotechnology
Neuphoria Therapeutics Inc
$2.58
+0.00 (+0.00%)
Open$2.64
Previous Close$2.58
Day High$2.64
Day Low$2.56
52W High$5.53
52W Low$2.70
Volume—
Avg Volume46.1K
Market Cap14.99M
P/E Ratio—
EPS$-5.00
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+473.3% upside
Current
$2.58
$2.58
Target
$14.79
$14.79
$9.77
$14.79 avg
$16.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.44M | 5.17M | 4.87M |
| Net Income | -16,500,197 | -354,866 | -256,361 |
| Profit Margin | -1,145.7% | -6.9% | -5.3% |
| EBITDA | -19,365,436 | -507,265 | -425,609 |
| Free Cash Flow | — | -183,163 | -132,058 |
| Rev Growth | — | -7.1% | +6.1% |
| Debt/Equity | 0.00 | 0.39 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |